JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M206187200 on September 16, 2002

J. Biol. Chem., Vol. 277, Issue 47, 44623-44630, November 22, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/47/44623    most recent
M206187200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, H.
Right arrow Articles by Laird-Offringa, I. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, H.
Right arrow Articles by Laird-Offringa, I. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Lipopolysaccharide-induced Methylation of HuR, an mRNA-stabilizing Protein, by CARM1*

Hongwei LiDagger , Sungmin Park§, Britta Kilburn||, Mary Anne Jelinek||, Agnes Henschen-Edman**, Dana W. Aswad**, Michael R. StallcupDagger §DaggerDagger, and Ite A. Laird-Offringa§DaggerDagger§§

From the Departments of Dagger  Pathology and § Biochemistry and Molecular Biology,  Norris Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, California 90089-9176, || Upstate Biotechnology, Inc., Lake Placid, New York 12946, and the ** Department of Molecular Biology and Biochemistry, University of California, Irvine, California 92697-3900

Received for publication, June 21, 2002, and in revised form, September 11, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The RNA-binding protein HuR stabilizes labile mRNAs carrying AU-rich instability elements. This mRNA stabilization can be induced by hypoxia, lipopolysaccharide, and UV light. The mechanism by which these stimuli activate HuR is unclear and might be related to post-translational modification of this protein. Here we show that HuR can be methylated on arginine. However, HuR is not a substrate for PRMT1, the most prominent protein-arginine methyltransferase in mammalian cells, which methylates a number of heterogeneous nuclear ribonucleoproteins. Instead, HuR is specifically methylated by coactivator-associated arginine methyltransferase 1 (CARM1), a protein-arginine methyltransferase previously shown to serve as a transcriptional coactivator. By analyzing methylation of specific HuR arginine-to-lysine mutants and by sequencing radioactively methylated HuR peptides, Arg217 was identified as the major HuR methylation site. Arg217 is located in the hinge region between the second and third of the three HuR RNA recognition motif domains. Antibodies against a methylated HuR peptide were used to demonstrate in vivo methylation of HuR. HuR methylation increased in cells that overexpressed CARM1. Importantly, lipopolysaccharide stimulation of macrophages, which leads to HuR-mediated stabilization of tumor necrosis factor alpha  mRNA in these cells, caused increased methylation of endogenous HuR. Thus, CARM1, which plays a role in transcriptional activation through histone H3 methylation, may also play a role in post-transcriptional gene regulation by methylating HuR.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Mammalian Hu proteins are a family of highly conserved RNA-binding proteins with homology to the Drosophila protein ELAV (embryonic lethal/altered visual system) (1, 2). The four Hu protein family members are HuR (also called HuA), HuB (previously called Hel-N1), HuC, and HuD (3-6). The last three are neuronal proteins, whereas HuR is ubiquitously expressed (2, 3, 7). Structurally, HuR has two closely spaced N-terminal RNA recognition motif domains (RRMs),1 followed by a hinge region of about 50 residues and a C-terminal RRM (3). Immunostaining shows HuR to be predominantly nuclear; however, the protein has been shown to shuttle between nucleus and cytoplasm (8-11). HuR can bind to AU-rich elements (AREs) in the 3'-untranslated region of unstable mRNAs (3, 12-22). Overexpression of HuR in transiently transfected mammalian cells stabilizes such short lived ARE-containing mRNAs, suggesting its involvement in the regulation of mRNA stability (8, 10, 11, 13, 15-18, 20, 23, 24). Stabilization of specific mRNAs by HuR has been observed in cancer cells (14, 17) and following certain extracellular stimuli. For example, HuR mediates the stabilization of p21 mRNA upon exposure of cells to UV light (19), of vascular endothelial growth factor mRNA by hypoxia (15), of nitric-oxide synthase II mRNA upon cytokine stimulation (13), and of tumor necrosis factor (TNF)-alpha mRNA upon stimulation with lipopolysaccharide (LPS) (18). At present, it is unclear how such inducible stabilization of mRNAs by HuR is controlled.

Heterogeneous nuclear ribonucleoproteins (hnRNPs) are among the most commonly methylated proteins in mammalian cells, but other RNA-binding proteins are also substrates for methylation in vitro and in vivo (25-35). Protein arginine methyltransferases (PRMTs) transfer the methyl group from S-adenosylmethionine (AdoMet) to specific arginines in substrate proteins (26, 36). Thus far, cDNA clones encoding six genetically distinct but related mammalian PRMTs have been isolated. PRMT1 is the major arginine methyltransferase in mammals (37) and is essential for early development of mouse embryos (38). Besides methylating hnRNPs, PRMT1 can methylate other nucleic acid-binding proteins, such as poly(A)-binding protein 2, fibrillarin, nucleolin, and histone H4 in vivo (26-28, 37, 39-41). Coactivator-associated arginine methyltransferase 1 (CARM1/PRMT4), which was originally discovered by its interaction with glucocorticoid receptor-interacting protein 1 in a yeast two-hybrid screen (42), methylates histone H3 (42-44) and p300/CBP (45) in vivo. Specific protein substrates have also been identified for PRMT3, JBP1 (PRMT5), and PRMT6, but no substrates have been reported yet for PRMT2 (see Refs. 46 and 47 and references therein). Thus far, arginine methylation of proteins has been implicated in the regulation of gene transcription, signal transduction, and nuclear-cytoplasmic protein transport (36, 47). Recent studies have revealed changes in cellular levels of protein arginine methylation after a variety of stimuli. For example, the increased methylation of STAT1 parallels its enhanced transcription activation function in response to interferon alpha /beta (48). CARM1-directed arginine methylation of histone H3 in the promoters of steroid hormone-responsive genes is induced by steroid hormone treatment of cells (43). CARM1 methylation also appears to inhibit cAMP-mediated gene expression, preventing the association between transcription factor CREB and cofactor CBP/p300 by methylation of the p300 domain required for CREB binding (45). Thus, it appears that, like phosphorylation and acetylation, methylation may play an important role in the transduction of extracellular signals to the transcription machinery.

Here, we present evidence that CARM1-directed methylation may also be involved in gene regulation at the post-transcriptional level. We show that HuR associates with and is specifically methylated in vitro by CARM1. Using antibodies that specifically recognize the methylated form of HuR, we demonstrate that HuR is methylated in vivo. The level of HuR methylation is altered by overexpression of CARM1 or by stimulation of macrophages with LPS, which is known to cause HuR-mediated mRNA stabilization (18). Our data suggest that methylation by CARM1 plays a role in mRNA stabilization by HuR.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- COS-7 and RAW 264.7 cells were maintained in Dulbecco's modified Eagle's medium, and Jurkat cells were maintained in RPMI 1640, each supplemented with 1% penicillin and streptomycin and 10% fetal bovine serum. LPS (Sigma) was added into the medium at 10 µg/ml for 1 h to stimulate RAW 264.7 cells.

Plasmids, Peptides, and Antibody Production-- Construction of plasmids pSG5-HA-CARM1 and pGEX-4T1-CARM1 has been previously reported (42). To construct plasmid pET3d-HuR for the expression of full-length recombinant human HuR protein, the coding region was amplified from pGST-HuR (3) by high fidelity PCR using oligonucleotides to engineer an NcoI-compatible BspHI site at the ATG and an NotI site immediately following the last codon of the HuR cDNA. The BspHI-NotI HuR cDNA fragment was inserted into an NcoI-NotI-digested derivative of the pET3d vector (Novagen) encoding a C-terminal hexahistidine and c-myc epitope tag (49), yielding pET3d-HuR. The HuR hinge region mutants were made by first creating a BssHII site (GCG/CGC at alanine 204/arginine 205) and an ApaI site (GGG/CCC at glycine 209/proline 210) with silent mutations, resulting in plasmid H918. Bold indicates which nucleotide was mutated to generate the restriction site. The HuR hinge deletion mutant was then made by digestion of H918 with BssHII and NcoI (at methionine 223), blunting, and religation, resulting in deletion of amino acids Arg206-Pro222. The individual arginine-to-lysine hinge region mutants were made by digestion of H918 at preexisting sites PvuII (at glutamine 198/leucine 199) or NcoI (at methionine 223) or the engineered BssHII or ApaI sites (see above), and replacing the intervening sequences with double-stranded oligonucleotides encoding the desired mutation. This approach yielded HuR arginine-to-lysine mutants R205K, R206K, R217K, and R219K in the pET3d derivative. The eukaryotic HuR expression plasmids were created from the pET3d constructs by excising the coding region using an EcoRI site just upstream of the ATG and the NotI site just downstream of the last codon and inserting this HuR fragment into a modified vector derived from pSG5-HA (42), so that an N-terminal hemagglutinin tag and a C-terminal hexahistidine tag were fused on either end. The resulting HA-HuR protein carried the following additional amino acids: N-terminal to HuR methionine 1, MGYPYDVPDYAEF; C-terminal to HuR Lys326, AAAHHHHHH-stop. GST-PRMT1 (41), GST-PRMT3 (50), GST-GAR (41), and GST-hnRNP K (51) expression vectors have been previously described. GST-PRMT2 was kindly provided by Dr. Steven Clarke (UCLA). Peptide P1 (HYHSPARRFGGPVHHQAQRFRFSPMGV-NH2) (AnaSpec Inc.) encoding the HuR hinge domain was generated for in vitro methylation and radiosequencing analysis. To raise an antibody that could specifically recognize methylated HuR (anti-me(R217)HuR antibody), methylated peptide HHQAQ(DMA)FRFSPGC (where DMA represents asymmetric dimethylarginine) was synthesized and conjugated to keyhole limpet hemocyanin before injection into rabbits. Specificity of the antiserum was confirmed by enzyme-linked immunosorbent assays with the DMA-containing peptide and a corresponding unmethylated peptide.

Transfection-- Approximately 20 h prior to transfection, 1.0 × 106 COS-7 cells were seeded onto 100-mm dishes. Cells were transiently transfected with methyltransferase expression vectors and/or HuR expression vectors by transfection reagent F-2 (Targeting Systems) according to the manufacturer's protocol. Approximately 48 h after transfection, cell extracts were prepared by scraping cells into RIPA (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% (v/v) Nonidet P-40, 0.1% (w/v) SDS, and protease inhibitor mixture tablets (Roche Molecular Biochemicals)), followed by centrifugation at 12,000 rpm for 30 min.

Immunoprecipitation and Immunoblot-- Cell lysates, prepared as described above (one 100-mm dish of cells/immunoprecipitation sample), were cleared with protein A/G beads (Santa Cruz Biotechnology, Inc.) for 1 h at 4 °C. 2 µg of anti-met(R217)HuR or anti-mono/dimethyl arginine (Ab412; Abcam Ltd.) were added to the cell lysates and incubated overnight at 4 °C on a rotator. Protein A/G beads were added and incubated for another 3 h. Beads were washed three times with radioimmune precipitation buffer and subjected to SDS-PAGE. Blots were probed with mouse monoclonal anti-HuR (Santa Cruz Biotechnology) at 1 µg/20 ml of blocking buffer (5% (w/v) nonfat milk in TBST: 150 mM NaCl, 10 mM Tris-HCl, pH 8.0, and 0.1% (v/v) Tween 20). Horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology) were used at 1 µg/10 ml of blocking buffer and ECL reagents (Amersham Biosciences) were used for detection.

In Vitro Protein-Protein Interaction-- GST fusion proteins were produced in Escherichia coli BL21 as described previously (52). Hexahistidine fusion proteins were purified with His-Bind Buffer Kit (Novagen) according to the manufacturer's protocol. Pull-down assays were conducted as described previously (53). CARM1 protein was translated in vitro in the presence of [35S]methionine using the TNT-T7-coupled reticulocyte lysate system (Promega). The binding assay was conducted by incubating beads containing 2 µg of His-HuR with slow rotation overnight at 4 °C with 10 µl of the translation reaction in a 500-µl total volume of NETN-0.01% (100 mM NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 7.0, and 0.01% (v/v) Nonidet P-40). Beads were washed four times with NETN-0.01% and analyzed by SDS-PAGE and autofluorography.

Methylation Assay-- Methyltransferases were prepared as recombinant GST fusion proteins and eluted from glutathione-agarose beads (Sigma) with 20 mM glutathione. 0.5-3 µg of commercially obtained histone H3 (Roche Molecular Biochemicals) or recombinant proteins were incubated with 1 µg of methyltransferase in the presence of 6 µM S-adenosyl-[methyl-3H]methionine ([3H]AdoMet; 14.7 Ci/mmol; PerkinElmer Life Sciences) in reaction buffer (20 mM Tris-HCl, pH 8.0, 200 mM NaCl, and 0.4 mM EDTA) at 30 °C for 1 h in 35-µl reactions (42). SDS-loading buffer or radioimmune precipitation buffer was used to stop the reaction. Labeled proteins were identified by SDS-PAGE and autofluorography for 12 h. To prepare the in vitro methylated samples for immunoprecipitation, nonradiolabeled AdoMet was used instead at 0.1 mM.

Radiosequencing-- Approximately 5 µg (1.6 nmol) of [3H]methyl-HuR hinge peptide P1 was purified from a CARM1-catalyzed methylation reaction by reversed phase high performance liquid chromatography on a 2.1 × 30-mm RP-300 (C8) column (Brownlee Laboratories). Elution was carried out at 1.0 ml/min using a linear gradient of 5-40% (v/v) acetonitrile in 0.1% (v/v) trifluoroacetic acid, and the peptide was detected by monitoring absorbance at 214 nm. The purified [3H]methyl peptide was found to contain ~0.07 mol of [3H]methyl/mol of peptide. Two samples (650 pmol each) of the purified peptide were sequenced for 22 cycles by automated Edman degradation on a Hewlett-Packard G1105A sequenator. The first sample was sequenced by standard procedures to verify the correct amino acid sequence and to establish the repetitive yield. For the second sample, the phenylthiohydantoin-derivatized amino acids from each cycle were collected for measurement of 3H by liquid scintillation counting.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

HuR Is Specifically Methylated by CARM1 in Vitro-- Because it is unclear how extracellular signals mediate HuR-induced stabilization of labile ARE-containing mRNAs, we sought to establish whether post-translational modification of HuR might play a role. No modifications of HuR (including phosphorylation) have been found as yet. Because arginine methylation is a common modification of RNA-binding proteins, we tested whether HuR could be methylated by one of the PRMTs. Various recombinant PRMTs were incubated with recombinant hexahistidine-tagged HuR (His-HuR) in the presence of [3H]AdoMet, and the products were examined by SDS-PAGE and autofluorography. His-HuR was methylated by CARM1 but not by PRMT1, PRMT2, or PRMT3 (Fig. 1A, lanes 4-7). Staining of the gel demonstrated that His-HuR and PRMT proteins were present in the appropriate reactions (Fig. 1B, lanes 4-7), and methylation of known substrates for PRMT1, PRMT3, and CARM1 (hnRNPK, GAR, and histone H3, respectively) verified the specificity and activity of these PRMTs (Fig. 1A, lane 1-3). (No known substrate for PRMT2 is currently available as a control.) Methylation of degradation products of GST-hnRNP K and His-HuR and an aggregation product of histone H3 was also observed (Fig. 1A, lanes 1, 2, and 7).


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 1.   Specific methylation of HuR by CARM1 in vitro. A, in vitro methylation assay of various protein substrates by GST-PRMTs. 5 µg of GST-hnRNP K (lane 1), histone H3 (lane 2), GST-GAR (lane 3), and His-HuR (lanes 4-7) were incubated with 0.5-2 µg of GST-PRMTs as indicated. Reactions were resolved by SDS-PAGE and subjected to autofluorography. B, Coomassie staining of a gel run in parallel containing the identical reaction mix used for A (except for the absence of AdoMet) to show the presence of protein substrates (stars) and PRMTs (black arrows). Methylation of contaminants or dimers in Histone H3 and degradation products of GST-hnRNP K and His-HuR are indicated by black dots.

CARM1 and HuR Associate in Vitro-- To further test the substrate specificity of CARM1 for HuR, we investigated whether CARM1 could bind HuR directly in vitro. Either CARM1 or PRMT1 was translated in vitro in the presence of [35S]methionine (Fig. 2, lane 1) and incubated with protein-free Ni2+ beads, Ni2+ beads to which His-HuR had been bound, glutathione-agarose beads with bound GST, or glutathione-agarose beads to which GST-hnRNP K had been bound (Fig. 2, lanes 2-5). Strong interactions between CARM1 and His-HuR (lane 3) and between PRMT1 and hnRNP K (lane 5) were observed, whereas no association between the other combinations was detected. Thus, the substrate specificity observed in the in vitro methylation assay is supported by the selective association between the two PRMTs and their respective substrates.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Specific binding of HuR to CARM1. CARM1 (upper panel) and PRMT1 (lower panel) were translated in vitro in the presence of [35S]methionine and incubated with Ni2+ beads (lane 2), Ni2+ beads containing 5 µg of His-HuR (lane 3), GST-agarose beads (lane 4), or agarose beads containing 5 µg of GST-hnRNP K (lane 5). Bound proteins were analyzed by SDS-PAGE and autofluorography for 12 h. 10% of translation products used for binding were loaded on the gel for comparison (lane 1, input).

The HuR Hinge Region Harbors the Methylation Site(s)-- Whereas PRMT1 methylation sites are frequently located in Arg-Gly-Gly (RGG) repeats (26), neither histone H3, the first identified in vivo substrate for CARM1 (42), nor HuR contains RGG repeats. Based upon two CARM1 methylation sites in histone H3, a potential consensus motif, KAXRK, has been proposed (44). Whereas HuR does not contain KAXRK sequences, we noted that two arginines in the hinge region were preceded by alanine at the -2 position (PARRF and QAQRF) (Fig. 3A). We therefore tested whether an HuR mutant from which a 16-amino acid tract containing the two possible methylation sites had been deleted (Fig. 3A) could still be methylated. In contrast to intact HuR, which was strongly methylated (Fig. 3B, left panel, lane 1), no in vitro methylation of this deletion mutant by CARM1 was seen (Fig. 3B, left panel, lane 2), although similar quantities of mutant and wild type HuR proteins were used as substrates (Fig. 3B, right panel). This result suggests that the hinge region of HuR contains the methylation site(s) or is important for substrate recognition by CARM1.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 3.   Identification of the HuR methylation site. A, schematic diagram of HuR protein. The sequence of a portion of the HuR hinge region is shown between the dashed lines. The arginines in the hinge region are numbered. Amino acids deleted in the HuR(Delta hinge) mutant are indicated in boldface type. HuR amino acids included in the synthetic peptide P1 are marked. B, 2-3 µg of His-HuR (lane 1) or His-HuR(Delta hinge) (lane 2) were incubated with GST-CARM1 for an in vitro methylation assay. Samples were analyzed on two SDS-PAGE gels, one for autofluorography (left) and one for Coomassie staining (right). C, 2-3 µg of recombinant HuR point mutant proteins (lanes 1-4) and wild type HuR (lane 5) were subjected to an in vitro methylation assay with GST-CARM1. Autofluorography (upper panel) and Coomassie staining (lower panel) of the HuR proteins are shown. The positions of the point mutations are indicated in A.

To determine which of the four arginines located in hinge region (Fig. 3A) might be methylated, we generated four point mutants in the context of full-length HuR, each one containing a single arginine-to-lysine substitution. Mutation of arginine 217 to lysine (R217K) completely abolished in vitro methylation of HuR by CARM1, whereas each of the other three HuR mutants (R205K, R206K, and R219K) was methylated to a level comparable with that of wild type HuR (Fig. 3C). This suggests an essential role of Arg217 as the methylation site and/or as a residue that is important for recognition of HuR by CARM1.

We next synthesized a HuR hinge peptide, P1, containing all four arginines (Fig. 3A). CARM1 efficiently methylated the P1 peptide in vitro, whereas PRMT1 did not (Fig. 4A). Thus, the determinants that mark HuR as a CARM1 substrate are retained in the 27-amino acid P1 sequence. In order to establish directly the location of the methylation site(s), a sample of the peptide, [3H]methyl-labeled by CARM1, was subjected to radiosequencing by automated Edman degradation. Approximately 25% of the 3H was recovered in cycles 7-9, whereas the remaining 75% was recovered in cycles 18-22 (Fig. 4B). The first peak indicates selective methylation of Arg206. 3H recovery in cycles 18-22 includes both Arg217 and Arg219; however, the drop in 3H content from cycle 19 (Phe218) to cycle 20 (Arg219) was slightly greater than the drop in the preceding cycle, although the chemical yield of Arg219 was slightly greater than that of Arg217 as determined in a parallel sequencing run (data not shown). This indicates that nearly all of the 3H recovered in cycles 18-22 results from selective methylation of Arg217 with little or no contribution by Arg219. When the sequencing results in Fig. 4B are corrected for repetitive yield and lag (Fig. 4C), Arg217 and Arg206 account for 83 and 17% of the [3H]methyl incorporation, respectively. Thus, Arg217 is the major methylation site in the HuR hinge peptide when modified by CARM1 in vitro.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 4.   Mapping of the major HuR methylation site to Arg217. A, 5 µg of synthetic peptide P1 (Fig. 3A) or recombinant GST-hnRNP K were tested for in vitro methylation by either GST-CARM1 or GST-PRMT1 and analyzed by autofluorography (left panel) and Coomassie staining (right panel). Minor contaminants in P1 or degradation products of GST-hnRNP K were methylated as well. B, radiosequencing of in vitro methylated P1 was carried out as described under "Experimental Procedures." C, a refinement of data from B in which corrections were made for the ragged N terminus, for sequencing lag, and for a measured repetitive yield of 95%. Numbers above the bars refer to amino acid residue numbers in HuR.

HuR Is Methylated by CARM1 in Vivo-- To test whether HuR is methylated in vivo, we developed antibodies directed against HuR methylated at Arg217 (anti-me(R217)HuR). We also used an antibody that generally recognizes proteins containing mono- or dimethylarginine (anti-M/DMA), which has been used successfully to demonstrate the in vivo methylation of STAT1 (48) and hepatitis C virus NS3 protein (55). Both antibodies were characterized for discrimination between HuR methylated in vitro by CARM1 (using unlabeled AdoMet) and unmethylated HuR (Fig. 5). (The in vitro methylation was confirmed in a parallel reaction with [3H]AdoMet (data not shown).) Following immunoprecipitation by anti-me(R217)HuR or anti-M/DMA antibodies, the precipitated HuR protein was detected by immunoblot using antiserum raised against unmodified HuR protein. Both the anti-me(R217)HuR and anti-M/DMA antibodies specifically immunoprecipitated methylated HuR (Fig. 5). Although no HuR was detected in immunoprecipitates obtained with appropriate isotype control antibodies (data not shown), a small amount of HuR was precipitated from the unmethylated reaction with anti-me(R217)HuR antiserum (Fig. 5B, lane 1). This weak signal might be due to low levels of antibodies directed against parts of the peptide flanking the methylation site. Nevertheless, both anti-me(R217)HuR and anti-M/DMA antibodies were highly specific for methylated versus unmethylated HuR. Neither antibody could detect the in vitro methylated HuR on immunoblots (data not shown).


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 5.   Characterization of anti-me(R217)HuR antiserum. GST-CARM1 and GST-HuR were incubated with either 0.1 mM AdoMet (lane 2) or buffer (lane 1). A, 5 µg of the proteins used for immunoprecipitation were analyzed directly by immunoblot with anti-HuR antibodies. Approximately 100 ng of HuR from each reaction was subjected to immunoprecipitation with 1 µg of either anti-me(R217)HuR (B) or anti-M/DMA (C) antibody. Immunoprecipitates were resolved by SDS-PAGE and probed with anti-HuR to detect the precipitated HuR.

In order to determine whether HuR can be methylated by CARM1 in vivo, we co-transfected COS-7 cells with expression vectors encoding HA-tagged CARM1 and either HA-HuR (Fig. 6A, lane 2) or HA-HuR(R217K) (lane 4). COS-7 cells transfected with HA-HuR alone (lane 1) or HA-HuR(R217K) alone (lane 3) were used as controls. Cell lysates were then subjected to immunoprecipitation with either anti-M/DMA antibody or anti-me(R217)HuR antibody, and immunoprecipitated HA-HuR was detected by immunoblotting using an anti-HA antibody. Whereas the expression level of HA-HuR was similar in all four samples (Fig. 6A), expression of HA-CARM1 substantially increased the amount of HA-HuR immunoprecipitated by both methyl-directed antibodies (Fig. 6, B and C, compare lanes 1 and 2) but had no effect on the amount of HA-HuR(R217K) immunoprecipitated (compare lanes 3 and 4). These results demonstrate that HuR can be methylated in vivo by CARM1 and support the notion that Arg217 is the major methylation site in vivo as well as in vitro.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 6.   Detection of HuR methylation in vivo. COS-7 cells were transiently transfected with 5 µg each of expression vectors for HA-HuR, HA-HuR(R217K), and HA-CARM1 in the combinations indicated, and cell extracts were prepared. A, 5% of each cell extract was loaded for comparison. The extracts were subjected to immunoprecipitations with either anti-me(R217)HuR antibody (B) or anti-M/DMA (C). All three blots were probed with anti-HA.

HuR Methylation Is Enhanced in RAW 264.7 Cells Treated with LPS-- Having demonstrated that HuR methylation occurs in vivo, we next asked whether this post-translational modification could play any role in the regulation of gene expression by HuR. HuR can bind to AREs present in a large variety of mRNAs, including those encoding mediators of inflammation (13, 17, 18, 23). This binding of HuR has been linked to stabilization of mRNAs encoding interleukin-3, nitric-oxide synthase II, and TNF-alpha , which are induced by ionophores, 12-O-tetradecanoylphorbol 13-acetate, cytokines, or LPS, depending on the cell type (13, 17, 18, 23). Recently, interferon (IFN) signaling, another component of the inflammatory response, was shown to be mediated at least in part through increased methylation of STAT1, an IFN-activated transcription factor (48). A role for arginine methylation in IFN signaling was supported by the observation that the IFN-alpha receptor interacts with PRMT1 and that antisense PRMT1 oligonucleotides mitigated the IFN response (56). Whereas CARM1 appears to play a role in steroid hormone and cAMP-mediated signaling, there has as yet been no evidence for its involvement in the inflammatory response. However, its ability to methylate HuR, combined with the observed role of HuR in the mRNA stabilization following inflammatory stimuli in a variety of cells, suggested that CARM1 methylation might play a role in the inflammatory response as well. We therefore tested whether the in vivo methylation status of HuR might change in LPS-stimulated RAW 264.7 cells (a murine macrophage-like cell line). RAW 264.7 cells respond to LPS by strongly inducing TNF-alpha expression, mediated in part through TNF-alpha mRNA stabilization by HuR binding (18).

We first determined by immunoblot that RAW 264.7 cells contain CARM1 protein (data not shown). Then cell lysates from either untreated or LPS-treated RAW 264.7 cells were analyzed by immunoprecipitation with anti-me(R217)HuR antibody (Fig. 7A) followed by immunoblotting with anti-HuR. The total level of HuR protein in the cells was not increased by LPS treatment (Fig. 7A, input samples). Whereas HuR was barely detectable when lysates from unstimulated RAW 264.7 cells were used for immunoprecipitation, a strong HuR band became visible upon LPS stimulation (Fig. 7A, lanes 3-5). These observations suggest that methylation of HuR occurs in response to LPS stimulation. A similar observation was made when Jurkat cells, a human T cell leukemia cell line that responds to a wide variety of agents, including LPS (57), was examined for induction of HuR methylation (Fig. 7B). Since the anti-me(R217)HuR antibodies specifically recognize methylated HuR and CARM1 is the only one of the four PRMTs tested that can utilize HuR as a substrate, our results strongly suggest that CARM1 methylates HuR in response to LPS and indicate that CARM1 might play a role in LPS-mediated mRNA stabilization.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 7.   Regulation of HuR methylation in vivo by LPS. A, RAW 264.7 cells received no LPS (lanes 1 and 4) or were treated with LPS at 10 µg/ml in cell culture medium for 1 h (lanes 2, 3, and 5). Cell extracts were incubated overnight at 4 °C with 1 µg of either normal mouse IgG or anti-me(R217)HuR antibodies as indicated, resolved by SDS-PAGE, and probed with anti-HuR. 5% of each cell extract used for immunoprecipitation was loaded for comparison (input lanes; a shorter exposure confirms that signal in both input lanes is very similar). B, Jurkat cells were untreated or treated with LPS at 10 µg/ml in cell culture medium for 1 h. Cell extracts were incubated overnight at 4 °C with 1 µg of anti-me(R217)HuR antibodies, resolved by SDS-PAGE, and probed with anti-HuR. 5% of each cell extract used for immunoprecipitation was loaded for comparison (input lanes).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We have identified a new target for arginine methylation by CARM1: the RNA-binding protein HuR. HuR is methylated by CARM1 in vitro but not by PRMT1, -2, or -3 (Fig. 1). Analysis of arginine-to-lysine mutants of HuR indicated that Arg217 is the major methylation target site (Fig. 3). Radiosequencing of a HuR hinge peptide methylated in vitro supported this conclusion but also identified Arg206 as a possible minor methylation site (Fig. 4). However, since Arg206 was not methylated in full-length HuR carrying the R217K mutation (Fig. 3), methylation at Arg206 is either dependent on the presence of Arg217 (in the methylated or unmethylated form) or does not happen in the context of the full-length protein, perhaps because it is not accessible. Major and minor methylation sites have been observed in other CARM1 substrates (44, 45, 58), but their significance is presently unclear.

Whereas PRMT1 methylates many RNA-binding proteins at arginine residues in so-called RGG repeats (26, 47), the sequence specificity of CARM1 is not clear at present. However, a sequence or structural context that affects specificity must exist, because Arg205 and Arg219 in the same peptide are not methylated (Fig. 4), and CARM1 methylated only a few proteins in a large membrane-bound array of polypeptides (58). Recently, CBP/p300 and poly(A)-binding protein 1 (PABP1) were also identified as CARM1 substrates (45, 58). Comparison of all known major CARM1 target sites with those of HuR does not yield any obvious consensus, apart from the alanine at position -2, which is present in four of six previously identified major CARM1 methylation sites (Table I) and the fact that two major methylation sites are found in each protein, separated by 23 amino acids or fewer.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Comparison of previously identified CARM1 methylation sites with HuR targets

Since antibodies against a HuR peptide methylated at Arg217 (Fig. 5) immunoprecipitated increased amounts of HuR, but not HuR(R217K) from COS-7 cells overexpressing CARM1 (Fig. 6), we conclude that Arg217 is the major CARM1 methylation site in HuR, both in vitro and in vivo. To determine whether HuR methylation levels might be modulated in response to certain signals, we studied HuR methylation in RAW 264.7 cells stimulated with LPS. HuR has been shown to mediate stabilization of TNF-alpha mRNA in macrophages following LPS stimulation. The mechanism by which this occurs appears to be competition of HuR with the destabilizing protein tristetraproline for binding to the TNF-alpha mRNA ARE (18, 23, 59). Using our anti-methyl-HuR antibody, we showed that HuR methylation was increased in RAW 264.7 cells following LPS treatment (Fig. 7). This observation suggests that methylation by CARM1 might play a role in post-transcriptional gene regulation following inflammatory stimuli.

What could the effect of HuR methylation be, and how could this lead to mRNA stabilization? Immunostaining experiments had previously suggested that HuR was mainly nuclear, but heterokaryon analyses and cell fractionation experiments have demonstrated that the protein shuttles between the nucleus and cytoplasm (8-11). Only cytoplasmic HuR would be able to stabilize mRNA. Thus, one possible function of HuR methylation might be to raise its cytoplasmic concentration by increasing HuR export from the nucleus. Changes in intracellular localization caused by methylation have been observed for hnRNP A2 in mammalian cells and the yeast protein Np13p, which are substrates of mammalian PRMT1 and its yeast homologue RMT1, respectively. Intriguingly, methylation can have opposite effects on the intracellular location of these proteins, promoting a nuclear localization for hnRNPA2 (60) but stimulating a cytoplasmic location for Np13p (61). Methylation does not affect the charge of arginine residues but could cause steric changes and prevent hydrogen bond formation. Thus, it is assumed that changes in intracellular location caused by methylation result from altered protein/protein interactions.

Shuttling of HuR is mediated by sequences in the hinge region between RRMs 2 and 3 (amino acids 205-237 (Fig. 3), referred to as the HuR nucleocytoplasmic shuttling sequence, or HNS (8)). Interestingly, Arg206 and Arg217 are located within the HNS. Shuttling of HuR is thought to be influenced by proteins that interact with the HNS (such as pp32 and APRIL), thereby linking HuR to one or more nuclear export pathways (16, 62, 63). Methylation of the hinge domain could modify the interaction between HuR and the export machinery. In this respect, it is of great interest that the HuR export pathway appears to change following exposure of cells to stress, which increases export of HuR by the CRM1 pathway (62-64). The molecular mechanism for this switch has not yet been identified and may be related to methylation.

Whereas it is attractive to propose that methylation might increase nuclear export, an increase in cytoplasmic RNA-bound HuR could also be explained by alternative mechanisms. For example, methylation could prevent reimport of cytoplasmic HuR into the nucleus, lead to stabilization of cytoplasmic HuR protein, or alter HuR RNA-binding properties to favor binding to AU-rich sequences, thereby indirectly contributing to cytoplasmic accumulation of HuR. Whether methylation and shuttling are directly linked may be difficult to determine; distinguishing methylation effects from shuttling effects will be challenging, because the Arg217 methylation site is located in the shuttling sequence.

Whether methylation of proteins can affect their nucleic acid-binding properties remains unclear. Methylation of hnRNP A1 appears to have a moderate effect on its ability to bind to homopolymers (65). The RGG domains methylated in many RNA-binding proteins can participate in RNA binding, and their methylation may therefore influence the RNA/protein interaction (66). In the case of HuR, Arg217 lies outside the three RNA-binding domains, and a prominent role for the hinge region in RNA binding seems unlikely. Nevertheless, methylation could indirectly influence RNA binding, by affecting the interaction with hinge-binding proteins, which could in turn modulate RNA binding, perhaps by controlling the access of RRM2 and/or RRM3 to RNA (67).

One of the most intriguing questions that remains unanswered is whether methylation is dynamic. To date, no demethylase has been identified, and if such an enzyme does not exist, a signal achieved through increased methylation must be silenced by protein degradation or sequestration of the methylated protein. It has also been suggested that methylation could be an incremental signal, accumulating slowly on proteins that carry multiple methylation sites (36). This is not likely to be the case for HuR, since the response to LPS is rapid (within 1 h) and there appears to be only one or two methylation sites.

In conclusion, CARM1, which was previously identified as a transcriptional coactivator for nuclear receptors (42, 43), now appears to extend its role into the post-transcriptional domain of gene regulation. The potential for CARM1 involvement in post-transcriptional regulation of genes in response to a variety of stimuli is considerable, since one of its targets (HuR) not only mediates the stabilization of TNF-alpha mRNA upon stimulation with LPS (18) but also the stabilization of p21 mRNA upon exposure of cells to UV light (19), of vascular endothelial growth factor mRNA by hypoxia (15), and of nitric-oxide synthase II mRNA upon cytokine stimulation (13). How broad the regulatory network modulated by CARM1 might be will depend on how many target proteins it methylates in vivo. Thus far, CARM1 appears to have markedly fewer substrates than PRMT1 (36, 47, 58), but its recently demonstrated ability to methylate poly(A)-binding protein 1 (58) further supports its potential role in post-transcriptional gene regulation. Our results suggest that methylation by CARM1 might create a link between transcriptional and post-transcriptional events, affecting RNA synthesis as well as RNA transport and/or stability, and that methylation of the shuttling RNA-binding protein HuR may be one way in which nuclear and cytoplasmic regulation is coupled.

    ACKNOWLEDGEMENTS

We thank Dr. Michael M. Lai (University of Southern California) for kindly providing the pGEX4T1-hnRNP K plasmids and Dr. Henry Furneaux (Memorial Sloan Kettering Cancer Center, New York) for the GST-HuR plasmid. We thank Dr. Harvey R. Herschman (UCLA) for kindly providing the pGEX4T1-PRMT1, pGEX4T1-PRMT2, pGEX4T1-PRMT3, and pGEX4T1-GAR plasmids. We also thank Daniel Gerke for technical assistance and members of the Laird-Offringa laboratory for critical comments on the manuscript.

    FOOTNOTES

* This work was supported by United States Public Health Service Grants DK55274 (to M. R. S.) and NS17269 (to D. W. A.) from the National Institutes of Health and by American Cancer Society Institutional Research Grant IRG-21-37, a grant from the American Lung Association, and National Institutes of Health Grant R29CA78407 (to I. A. L-O.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Dagger These authors contributed equally to this work.

§§ To whom correspondence should be addressed: Norris Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA 90089-9176. Tel.: 323-865-0655; Fax: 323-865-0158; E-mail: ilaird@usc.edu.

Published, JBC Papers in Press, September 16, 2002, DOI 10.1074/jbc.M206187200

    ABBREVIATIONS

The abbreviations used are: RRM, RNA recognition motif; AdoMet, S-adenosylmethionine; ARE, AU-rich element; CARM1, coactivator-associated arginine methyltransferase; CREB, cAMP-response element-binding protein; CBP, CREB-binding protein; DMA, asymmetric dimethylarginine; GAR, glycine-arginine rich peptide; GST, glutathione S-transferase; HA, hemagglutinin; hnRNPs, heterogeneous nuclear ribonucleoprotein particles; HNS, HuR nucleocytoplasmic shuttling sequence; IFN, interferon; LPS, lipopolysaccharide; PRMT, protein-arginine methyltransferase; TNF, tumor necrosis factor.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Antic, D., and Keene, J. D. (1997) Am. J. Hum. Genet. 61, 273-278[Medline] [Order article via Infotrieve]
2. Keene, J. D. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 5-7[Free Full Text]
3. Ma, W. J., Cheng, S., Campbell, C., Wright, A., and Furneaux, H. (1996) J. Biol. Chem. 271, 8144-8151[Abstract/Free Full Text]
4. Levine, T. D., Gao, F., King, P. H., Andrews, L. G., and Keene, J. D. (1993) Mol. Cell. Biol. 13, 3494-3504[Abstract/Free Full Text]
5. Liu, J., Dalmau, J., Szabo, A., Rosenfeld, M., Huber, J., and Furneaux, H. (1995) Neurology 45, 544-550[Abstract/Free Full Text]
6. Szabo, A., Dalmau, J., Manley, G., Rosenfeld, M., Wong, E., Henson, J., Posner, J. B., and Furneaux, H. M. (1991) Cell 67, 325-333[CrossRef][Medline] [Order article via Infotrieve]
7. Okano, H. J., and Darnell, R. B. (1997) J. Neurosci. 17, 3024-3037[Abstract/Free Full Text]
8. Fan, X. C., and Steitz, J. A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 15293-15298[Abstract/Free Full Text]
9. Atasoy, U., Watson, J., Patel, D., and Keene, J. D. (1998) J. Cell Sci. 111, 3145-3156[Abstract]
10. Fan, X. C., and Steitz, J. A. (1998) EMBO J. 17, 3448-3460[CrossRef][Medline] [Order article via Infotrieve]
11. Peng, S. S., Chen, C. Y., Xu, N., and Shyu, A. B. (1998) EMBO J. 17, 3461-3470[CrossRef][Medline] [Order article via Infotrieve]
12. Di Marco, S., Hel, Z., Lachance, C., Furneaux, H., and Radzioch, D. (2001) Nucleic Acids Res. 29, 863-871[Abstract/Free Full Text]
13. Rodriguez-Pascual, F., Hausding, M., Ihrig-Biedert, I., Furneaux, H., Levy, A. P., Forstermann, U., and Kleinert, H. (2000) J. Biol. Chem. 275, 26040-26049[Abstract/Free Full Text]
14. Nabors, L. B., Gillespie, G. Y., Harkins, L., and King, P. H. (2001) Cancer Res. 61, 2154-2161[Abstract/Free Full Text]
15. Levy, N. S., Chung, S., Furneaux, H., and Levy, A. P. (1998) J. Biol. Chem. 273, 6417-6423[Abstract/Free Full Text]
16. Brennan, C. M., and Steitz, J. A. (2001) Cell Mol. Life Sci. 58, 266-277[CrossRef][Medline] [Order article via Infotrieve]
17. Dixon, D. A., Tolley, N. D., King, P. H., Nabors, L. B., McIntyre, T. M., Zimmerman, G. A., and Prescott, S. M. (2001) J. Clin. Invest. 108, 1657-1665[CrossRef][Medline] [Order article via Infotrieve]
18. Dean, J. L., Wait, R., Mahtani, K. R., Sully, G., Clark, A. R., and Saklatvala, J. (2001) Mol. Cell. Biol. 21, 721-730[Abstract/Free Full Text]
19. Wang, W., Furneaux, H., Cheng, H., Caldwell, M. C., Hutter, D., Liu, Y., Holbrook, N., and Gorospe, M. (2000) Mol. Cell. Biol. 20, 760-769[Abstract/Free Full Text]
20. Wang, W., Caldwell, M. C., Lin, S., Furneaux, H., and Gorospe, M. (2000) EMBO J. 19, 2340-2350[CrossRef][Medline] [Order article via Infotrieve]
21. Maurer, F., Tierney, M., and Medcalf, R. L. (1999) Nucleic Acids Res. 27, 1664-1673[Abstract/Free Full Text]
22. Raghavan, A., Robison, R. L., McNabb, J., Miller, C. R., Williams, D. A., and Bohjanen, P. R. (2001) J. Biol. Chem. 276, 47958-47965[Abstract/Free Full Text]
23. Ming, X. F., Stoecklin, G., Lu, M., Looser, R., and Moroni, C. (2001) Mol. Cell. Biol. 21, 5778-5789[Abstract/Free Full Text]
24. Ford, L. P., Watson, J., Keene, J. D., and Wilusz, J. (1999) Genes Dev. 13, 188-201[Abstract/Free Full Text]
25. Liu, Q., and Dreyfuss, G. (1995) Mol. Cell. Biol. 15, 2800-2808[Abstract]
26. Gary, J. D., and Clarke, S. (1998) Prog. Nucleic Acids Res. Mol. Biol. 61, 65-131[Medline] [Order article via Infotrieve]
27. Smith, J. J., Rucknagel, K. P., Schierhorn, A., Tang, J., Nemeth, A., Linder, M., Herschman, H. R., and Wahle, E. (1999) J. Biol. Chem. 274, 13229-13234[Abstract/Free Full Text]
28. Najbauer, J., Johnson, B. A., Young, A. L., and Aswad, D. W. (1993) J. Biol. Chem. 268, 10501-10509[Abstract/Free Full Text]
29. Valentini, S. R., Weiss, V. H., and Silver, P. A. (1999) RNA 5, 272-280[Abstract]
30. Mears, W. E., and Rice, S. A. (1996) J. Virol. 70, 7445-7453[Abstract]
31. Siebel, C. W., and Guthrie, C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13641-13646[Abstract/Free Full Text]
32. Kim, S., Merrill, B. M., Rajpurohit, R., Kumar, A., Stone, K. L., Papov, V. V., Schneiders, J. M., Szer, W., Wilson, S. H., Paik, W. K., and Williams, K. R. (1997) Biochemistry 36, 5185-5192[CrossRef][Medline] [Order article via Infotrieve]
33. Friesen, W. J., Massenet, S., Paushkin, S., Wyce, A., and Dreyfuss, G. (2001) Mol. Cell 7, 1111-1117[CrossRef][Medline] [Order article via Infotrieve]
34. Friesen, W. J., Paushkin, S., Wyce, A., Massenet, S., Pesiridis, G. S., Van Duyne, G., Rappsilber, J., Mann, M., and Dreyfuss, G. (2001) Mol. Cell. Biol. 21, 8289-8300[Abstract/Free Full Text]
35. Brahms, H., Meheus, L., de, B., V, Fischer, U., and Luhrmann, R. (2001) RNA 7, 1531-1542[Abstract]
36. McBride, A. E., and Silver, P. A. (2001) Cell 106, 5-8[CrossRef][Medline] [Order article via Infotrieve]
37. Tang, J., Frankel, A., Cook, R. J., Kim, S., Paik, W. K., Williams, K. R., Clarke, S., and Herschman, H. R. (2000) J. Biol. Chem. 275, 7723-7730[Abstract/Free Full Text]
38. Pawlak, M. R., Scherer, C. A., Chen, J., Roshon, M. J., and Ruley, H. E. (2000) Mol. Cell. Biol. 20, 4859-4869[Abstract/Free Full Text]
39. Wang, H., Huang, Z. Q., Xia, L., Feng, Q., Erdjument-Bromage, H., Strahl, B. D., Briggs, S. D., Allis, C. D., Wong, J., Tempst, P., and Zhang, Y. (2001) Science 293, 853-857[Abstract/Free Full Text]
40. Strahl, B. D., Briggs, S. D., Brame, C. J., Caldwell, J. A., Koh, S. S., Ma, H., Cook, R. G., Shabanowitz, J., Hunt, D. F., Stallcup, M. R., and Allis, C. D. (2001) Curr. Biol. 11, 996-1000[CrossRef][Medline] [Order article via Infotrieve]
41. Lin, W. J., Gary, J. D., Yang, M. C., Clarke, S., and Herschman, H. R. (1996) J. Biol. Chem. 271, 15034-15044[Abstract/Free Full Text]
42. Chen, D., Ma, H., Hong, H., Koh, S. S., Huang, S. M., Schurter, B. T., Aswad, D. W., and Stallcup, M. R. (1999) Science 284, 2174-2177[Abstract/Free Full Text]
43. Ma, H., Baumann, C. T., Li, H., Strahl, B. D., Rice, R., Jelinek, M. A., Aswad, D. W., Allis, C. D., Hager, G. L., and Stallcup, M. R. (2001) Curr. Biol. 11, 1981-1985[CrossRef][Medline] [Order article via Infotrieve]
44. Schurter, B. T., Koh, S. S., Chen, D., Bunick, G. J., Harp, J. M., Hanson, B. L., Henschen-Edman, A., Mackay, D. R., Stallcup, M. R., and Aswad, D. W. (2001) Biochemistry 40, 5747-5756[CrossRef][Medline] [Order article via Infotrieve]
45. Xu, W., Chen, H., Du, K., Asahara, H., Tini, M., Emerson, B. M., Montminy, M., and Evans, R. M. (2001) Science 294, 2507-2511[Abstract/Free Full Text]
46. Frankel, A., Yadav, N., Lee, J., Branscombe, T. L., Clarke, S., and Bedford, M. T. (2002) J. Biol. Chem. 277, 3537-3543[Abstract/Free Full Text]
47. Stallcup, M. R. (2001) Oncogene 20, 3014-3020[CrossRef][Medline] [Order article via Infotrieve]
48. Mowen, K. A., Tang, J., Zhu, W., Schurter, B. T., Shuai, K., Herschman, H. R., and David, M. (2001) Cell 104, 731-741[CrossRef][Medline] [Order article via Infotrieve]
49. Laird-Offringa, I. A., and Belasco, J. G. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11859-11863[Abstract/Free Full Text]
50. Tang, J., Gary, J. D., Clarke, S., and Herschman, H. R. (1998) J. Biol. Chem. 273, 16935-16945[Abstract/Free Full Text]
51. Lau, J. S., Baumeister, P., Kim, E., Roy, B., Hsieh, T. Y., Lai, M., and Lee, A. S. (2000) J. Cell. Biochem. 79, 395-406[CrossRef][Medline] [Order article via Infotrieve]
52. Hong, H., Kohli, K., Trivedi, A., Johnson, D. L., and Stallcup, M. R. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4948-4952[Abstract/Free Full Text]
53. Ma, H., Hong, H., Huang, S. M., Irvine, R. A., Webb, P., Kushner, P. J., Coetzee, G. A., and Stallcup, M. R. (1999) Mol. Cell. Biol. 19, 6164-6173[Abstract/Free Full Text]
54. Myer, V. E., Fan, X. C., and Steitz, J. A. (1997) EMBO J. 16, 2130-2139[CrossRef][Medline] [Order article via Infotrieve]
55. Rho, J., Choi, S., Seong, Y. R., Choi, J., and Im, D. S. (2001) J. Virol. 75, 8031-8044[Abstract/Free Full Text]
56. Abramovich, C., Yakobson, B., Chebath, J., and Revel, M. (1997) EMBO J. 16, 260-266[CrossRef][Medline] [Order article via Infotrieve]
57. Manna, S. K., Mukhopadhyay, A., and Aggarwal, B. B. (2000) J. Immunol. 165, 4927-4934[Abstract/Free Full Text]
58. Lee, J., and Bedford, M. T. (2002) EMBO Rep. 3, 268-273[CrossRef][Medline] [Order article via Infotrieve]
59. Carballo, E., Lai, W. S., and Blackshear, P. J. (1998) Science 281, 1001-1005[Abstract/Free Full Text]
60. Nichols, R. C., Wang, X. W., Tang, J., Hamilton, B. J., High, F. A., Herschman, H. R., and Rigby, W. F. (2000) Exp. Cell Res. 256, 522-532[CrossRef][Medline] [Order article via Infotrieve]
61. Shen, E. C., Henry, M. F., Weiss, V. H., Valentini, S. R., Silver, P. A., and Lee, M. S. (1998) Genes Dev. 12, 679-691[Abstract/Free Full Text]
62. Gallouzi, I. E., Brennan, C. M., and Steitz, J. A. (2001) RNA 7, 1348-1361[Abstract]
63. Gallouzi, I. E., and Steitz, J. A. (2001) Science 294, 1895-1901[Abstract/Free Full Text]
64. Moore, M. J., and Rosbash, M. (2001) Science 294, 1841-1842[Free Full Text]
65. Rajpurohit, R., Paik, W. K., and Kim, S. (1994) Biochem. J. 304, 903-909[Medline] [Order article via Infotrieve]
66. Burd, C. G., and Dreyfuss, G. (1994) EMBO J. 13, 1197-1204[Medline] [Order article via Infotrieve]
67. Park, S., Myszka, D. G., Yu, M., Littler, S. J., and Laird-Offringa, I. A. (2000) Mol. Cell. Biol. 20, 4765-4772[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles: